Background {#s1}
==========

It is estimated that around 300 000 people who inject drugs (PWID) are living in Iran.[@R1] National statistics show injection drug use is still the principal mode of HIV transmission in Iran.[@R2] From 1986 to 2006, around 64% of new HIV cases were reported as acquiring the infection through injecting drug use. Recent evidence shows that the prevalence of HIV infection might be on a downward trend in this group.[@R3] However, the first Iranian national Bio-Behavioural Surveillance Survey (BBSS1) of HIV among PWID, conducted in 2008, found an alarmingly high HIV prevalence of 15.3%, with high levels of risky injection and sexual behaviours.[@R4]

More effective prevention and care response requires tracking the key features of the HIV epidemic. This paper therefore presents the results of the second round of BBSS (BBSS2) among male PWID in Iran, thereby establishing the current status of HIV infection and gauging the potential for further spread due to injection and sexual risk behaviours.

Methods {#s2}
=======

Setting and participants {#s2a}
------------------------

This cross-sectional survey was conducted in the same 10 provinces (out of 31) as in BBSS1. Based on the trend of identified HIV cases among PWID during 2000--2003, provinces were categorised in two strata: one stratum included the provinces with an upward trend, and the other included those with a downward or stable trend. From each stratum, five provinces were purposefully selected to provide the most disperse geographic representativeness.

In the current survey, between March and July 2010, using a facility-based sampling approach, PWID were recruited from drop-in centres, shelters, drug treatment centres, voluntary counselling and testing centres, and outreach spots in each selected province. Having the inputs from the officers in charge of the HIV surveillance system in each province, we selected a minimum of five different facilities in the capital city and neighbourhood cities (if feasible). Participants were recruited by convenience sampling at the centre regardless of their known or unknown HIV status and their verbal informed consent was requested to participate in the study. Eligible participants were men ≥18 years of age, who had injected drugs at least once during the past 12 months.

Data collection {#s2b}
---------------

A structured questionnaire was used to collect data on the demographic characteristics, and the key indicators of injection and sexual risk behaviours. Provincial supervisors trained and monitored the facility\'s staff to recruit, interview, and collect dried blood samples (DBS) based on a standard protocol. On completion of the behavioural survey, each subject was given an incentive of US\$1.5 (US\$2.5 in Tehran) in cash, and if agreed to be tested for HIV, they would get an additional US\$0.5. DBS samples were tested for HIV antibodies by ELISA (using bioMérieux Vironostika Uni-Form II Ag/Ab). All positives and 10% of the negative samples were rechecked in the Pasteur reference laboratory (using Bio-Rad Genscreen Plus HIV Ag-Ab); the κ coefficient was 95.8%.

Statistical analysis {#s2c}
--------------------

Multivariate logistic regression models were applied to determine the factors associated with HIV infection. Variables with a p value less than 0.2 in the bivariate analysis were entered into the multivariate model. In order to adjust for the clustering effects within facilities and provinces, and also to weight for the size of facilities, the survey function in Stata V.10 was used.

Results {#s3}
=======

A total of 2518 PWID were asked to participate in this study. Of these, 27 individuals did not meet the eligibility criteria, and 11 refused to provide informed consent (overall response rate 97.5%). Out of 2480 PWID, 2417 provided informed consent for HIV testing (response rate 97.5%). We were unable to complete the HIV test on 127 DBS as the specimen was not sufficient for HIV testing.

The overall prevalence of HIV was 15.2% (95% CI 9.7% to 23.1%); the highest and the lowest prevalence in different provinces were 31.9% and 2.2%, respectively. Among subgroups, unemployed PWID had the highest prevalence (20.1%), and those with above high school education had the lowest (4.6%). The mean (SD) age at the time of study, age at first drug use and age at first drug injection were 34.6 (8.9), 18.7 (5.2), and 25.9 (7.2) years, respectively. Over the past month, among those who had injected drugs, 36.9% had used a non-sterile needle and 12.6% had practiced shared injection. Over the past 12 months, 30.4% had sold sex for money, drugs, goods or a favour. In the multivariate model, HIV was significantly associated with current age, level of education and job status. Compared to the 18--25 age group, the adjusted ORs (AORs) of infection were 3.1 and 4.1 in the 26--35 and \>35 years age groups, respectively. Regarding the education level, AOR~(secondary\ and\ high\ school/above\ high\ school)~, AOR~(primary/above\ high\ school)~ and AOR~(illiterate/above\ high\ school)~ were 3.2, 3.1 and 2.7, respectively. Having a temporary job, and unemployment increased the AORs as well (3.1 and 4.6, respectively) ([table 1](#SEXTRANS2013051204TB1){ref-type="table"}).

###### 

Sociodemographic characteristics, risk behaviours and HIV infection among people who inject drugs in Iran, 2010

                                                                    \%                  HIV prevalence, N (%)   Bivariate model     Multivariate model                       
  ----------------------------------------------------------------- ------------------- ----------------------- ------------------- -------------------- ------------------- -------
  Current age (years)                                                                                                                                                        
   18--25                                                           13.9 (11.6--16.6)   7.8 (3.3--17.4)         Ref                 --                   Ref                 --
   26--35                                                           46.6 (43.9--49.3)   15.8 (10.1--23.8)       2.3 (1.2 to 4.4)    0.017                3.1 (1.6 to 6.1)    0.001
   ≥36                                                              39.5 (35.8--43.3)   17.0 (10.5--26.4)       2.4 (1.2 to 5.1)    0.018                4.1 (1.7 to 9.5)    0.002
  Age at first drug use (years)                                                                                                                                              
   ≤18                                                              56.7 (51.5--61.8)   14.2 (9.9--19.9)        Ref                 --                   \*                  \*
   \>18                                                             43.3 (38.2--48.5)   16.1 (8.5--28.4)        1.2 (0.6 to 2.1)    0.617                \*                  \*
  Age at first drug injection (years)                                                                                                                                        
   ≤25                                                              57.0 (52.9--60.9)   16.4 (10.1--25.6)       Ref                 --                   Ref                 --
   \>25                                                             43.0 (39.0--47.1)   13.2 (8.6--19.6)        0.8 (0.6 to 1.1)    0.164                0.7 (0.5 to 1.1)    0.106
  Marital status                                                                                                                                                             
   Currently married                                                31.2 (27.4--35.3)   13.2 (7.1--23.2)        Ref                 --                   Ref                 --
   Ever been married (divorced and widowed)                         21.5 (18.7--24.6)   16.7 (10.4--25.9)       1.3 (0.1 to 1.9)    0.164                1.1 (0.7 to 1.9)    0.605
   Single                                                           47.3 (43.6--51.0)   15.9 (10.2--23.8)       1.3 (0.8 to 2.1)    0.339                1.4 (0.7 to 2.6)    0.259
  Education                                                                                                                                                                  
   Above high school                                                4.5 (3.1--6.6)      4.6 (1.4--13.7)         Ref                 --                   Ref                 --
   Secondary and high school                                        65.2 (60.6--69.6)   15.6 (9.6--24.4)        3.8 (1.2 to 12.1)   0.024                3.2 (1.1 to 9.4)    0.039
   Primary school                                                   24.6 (21.3--28.2)   16.2 (9.6--26.0)        3.9 (1.2 to 12.6)   0.024                3.1 (1.1 to 8.7)    0.036
   Illiterate                                                       5.7 (3.5--9.2)      14.7 (7.9--25.6)        3.4 (0.9 to 12.6)   0.063                2.7 (0.7 to 9.8)    0.125
  Job status                                                                                                                                                                 
   Permanent job                                                    12.3 (7.5--19.7)    5.1 (1.9--12.5)         Ref                 --                   Ref                 --
   Temporary job                                                    48.9 (43.7--54.1)   13.8 (9.6--19.6)        3.3 (1.2 to 8.7)    0.020                3.1 (1.2 to 8.1)    0.025
   Unemployed                                                       38.8 (31.9--46.2)   20.1 (10.9--33.9)       5.2 (1.6 to 16.4)   0.006                4.6 (1.6 to 13.6)   0.007
  Having at least one injection in the last month                                                                                                                            
   No                                                               38.2 (29.2--48.1)   11.0 (6.8--17.2)        Ref                 --                   Ref                 --
   Yes                                                              61.8 (51.8--70.8)   17.8 (10.1--29.4)       1.7 (0.8 to 3.8)    0.178                1.7 (0.8 to 3.6)    0.184
  Using a used needle or syringe for injection in the last month†                                                                                                            
   No                                                               63.1 (55.0--70.6)   17.9 (9.6--30.9)        Ref                 --                   \*                  \*
   Yes                                                              36.9 (29.4--44.9)   17.6 (10.1--28.9)       0.9 (0.6 to 1.5)    0.903                \*                  \*
  Using a sterile needle or syringe at last injection                                                                                                                        
   No                                                               11.1 (8.3--14.6)    19.0 (10.6--31.5)       Ref                 --                   \*                  \*
   Yes                                                              88.9 (85.4--91.7)   14.7 (9.1--22.9)        0.8 (0.5 to 1.3)    0.368                \*                  \*
  Sharing injection tools with others over the last month†                                                                                                                   
   No                                                               87.4 (83.2--90.7)   18.5 (10.2--31.4)       Ref                 --                   \*                  \*
   Yes                                                              12.6 (9.3--16.8)    13.5 (7.9--22.2)        0.7 (0.3 to 1.5)    0.353                \*                  \*
  Sold sex during last 12 months                                                                                                                                             
   No                                                               69.6 (64.6--74.1)   15.1 (9.3--23.6)        Ref                 --                   \*                  \*
   Yes                                                              30.4 (25.9--35.4)   13.6 (9.5--21.3)        0.9 (0.6 to 1.2)    0.392                \*                  \*
  Condom use at last sexual intercourse‡                                                                                                                                     
   No                                                               61.7 (55.1--67.9)   13.4 (8.9--19.5)        Ref                 --                   \*                  \*
   Yes                                                              38.3 (32.0--44.9)   13.2 (6.1--26.2)        0.9 (0.5 to 2.1)    0.976                \*                  \*

\*Not entered into the multivariate model (p value in bivariate model was \>0.2).

†Among those who had at least one injection in the last month.

‡Among those who sold sex in exchange for money, drug, goods or any favour during the last 12 months.

Discussion {#s4}
==========

This survey showed that the prevalence of HIV among PWID in Iran is still alarmingly high, and behaviours for acquisition and transmission of HIV are common. The prevalence of HIV in BBSS1 (2008) and what we observed in this survey was remarkably similar (15.3% vs 15.2%).[@R4] However, the apparently stable prevalence of HIV must be considered as a dynamic balance of several competing or offsetting factors, including new infections against mortality of HIV-infected PWID, in against out migration, initiation against discontinuation of injection, and other factors such as incarceration and improved survival with antiretroviral therapy. Nonetheless, our data make a strong case that HIV transmission will remain a major health problem throughout Iran for the years to come.

In other high risk groups in Iran such as female sex workers, rather low levels of HIV prevalence (below 5%) are found compared to PWID.[@R5] Our findings confirm that PWID are still the most affected high risk group by HIV in Iran, with a prevalence of about 15%. Though this level of prevalence among PWID is rather high compared to other countries in the Middle East and North Africa, it is still lower than that found in other countries including Libya and Pakistan.[@R6] [@R7] This might be partly explained by our method of sampling, recruiting PWID from the facilities; however, other studies which recruited individuals through respondent driven sampling have also reported a high prevalence of HIV (25%) among PWID.[@R8]

Although there has been a history of prevention efforts among PWID in Iran, our findings potentially point to a sustained level of risky injection among PWID. While a large proportion of participants reported the use of sterile needles and syringes in their last injection, a considerable fraction still practice shared injections. Indeed, almost 40% of participants reported a history of using previously used needles during the month before the interview. Possible explanations may be peer pressure among PWID[@R9] [@R10] or having poor access to harm reduction services where and when they are needed the most.

In addition to risky injecting behaviours, sexual risk behaviours were relatively common among PWID. We found that selling sex in exchange for money, drugs, goods or a favour during the previous year were common; an issue that is difficult to address in the Iranian context. Iranian law outlaws male--male sex, which makes any explicit intervention regarding this behaviour even harder. Compounding the situation is that more than 60% of the participants reported not having used a condom in their last sexual encounter with a client. We think practical approaches are needed to slow down this potential mode of transmission among this population.

We acknowledge the limitations of our study. Our main sampling method (convenience sampling of those who seek services at the facilities) may limit the generalisation of the findings to all PWID in Iran, particularly those who are hidden and not linked to services. However, we tried to address such bias by recruiting from venues and hotspots of PWID through outreach activities. This method of sampling and recruitment is feasible given the geography and time constraints (more than 10 provinces over 4 months). It is also similar to that used in BBSS1 in 2008, thereby facilitating comparison with the results of that round.[@R4] As is common in behavioural surveys, social desirability may have affected the reporting of sensitive behaviours. Some sort of calibration may be needed to address this issue.[@R11]

In conclusion, injection and sexual risks are common among PWID and they still have the highest prevalence of HIV infection among the key populations in Iran. This high prevalence of HIV and its associated risky behaviours among PWID raise an alarm for the health authorities in Iran to design and implement effective and timely interventions to prevent further transmission among this population and to their partners.

###### Key messages

-   People who inject drugs (PWID) continue to have the highest HIV prevalence in Iran.

-   Unsafe injection and sex are still common among Iranian PWID.

-   Targeted HIV interventions tailored for the specific needs of PWID are critical to prevent further transmission of HIV among this high risk group and to other subpopulations.
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